Skip to content

EBITDA at other companies

Bausch + Lomb logo
Bausch + LombBLCO
$134M+483%
HRO
HarrowHROW
-$21.63M-101%
Johnson & Johnson logo
Johnson & JohnsonJNJ
Regeneron Pharmaceuticals logo
Regeneron PharmaceuticalsREGN
Glaukos logo
GlaukosGKOS
AbbVie logo
AbbVieABBV

Other financials

Income statement

See full
Operating income-$15.4M-108%
Net income-$13.8M-56.6%
EPS (diluted)-$0.69+82.6%

Balance sheet

See full
Cash & equivalents$238.9M+312%
Total debt$1.6M
Total equity$250.1M+463%
Total assets$258.4M

Cash flow

See full
Operating cash flow-$13.5M-65.2%
CapEx$676.0K+312%
Free cash flow-$14.2M-70.0%

Valuation

See full
Market cap$744.23M-10.9%
Enterprise value$506.93M

Returns & leverage

See full
Return on equity-34.3%
Debt / equity
Current ratio38×

Where this comes from

Calculated from Schering-Plough’s reported figures.

The official record: Schering-Plough’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Schering-Plough's ebitda.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Schering-Plough's EBITDA?
Schering-Plough (SGP) reported EBITDA of -$7.27M in Q1 2025.
How has Schering-Plough's EBITDA changed year-over-year?
Schering-Plough's EBITDA decreased by 8.5% year-over-year, from -$6.7M to -$7.27M.
What does EBITDA mean?
Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.